[Immune response to the vaccine (Hepavax B) against the B virus].
40 volunteers were vaccinated with a vaccine against hepatitis B (Hepavex B). All vaccines were at high risk to develop hepatitis B. After the third dose 37 (92.5%) of the vaccines, developed antibodies (HBsAb). The group more exposed to the virus B developed antibodies earlier, after the first dose. It is especulated that the earlier response could be anamnestic, due to previous inaparent contact with B virus. There were not serius side effects due to the vaccination.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D005260:Female; D006509:Hepatitis B / Q000276:immunology*; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010564:Personnel, Hospital; D014611:Vaccination; D014612:Vaccines
D000914:Antibodies, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D014612:Vaccines
Respuesta inmune a la vacuna (Hepavax B) contra el virus B.